A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)

Phase 1TerminatedNCT04022876

Aileron Therapeutics, Inc.35 enrolled

Overview

This is a Phase 1b, multicenter, 2-part study of ALRN-6924 for the prevention of chemotherapy-induced side effects. Part 1 SCLC is an open-label, multicenter study of ALRN-6924 for the prevention of chemotherapy-induced side effects in patients with p53-mutated ED SCLC undergoing 2nd-line treatment with topotecan. (Part 1 has completed enrollment). Part 2 NSCLC is a randomized, double-blind, placebo-controlled, multicenter study of ALRN-6924 for the prevention of chemotherapy-induced side effects in patients with p53-mutated advanced NSCLC of adenocarcinoma histology receiving 1st-line treatment with carboplatin plus pemetrexed with or without immunotherapy.

During Part 1 SCLC, topotecan will be administered per standard practice on Days 1-5 of 21-day cycles. Patients will be randomized to receive 1 of 2 initial ALRN-6924 dose levels, to be administered prior to each planned topotecan dose. The incidence, severity and duration of hematologic toxicities, including neutropenia, thrombocytopenia, and febrile neutropenia, will be determined. The safety and tolerability of each ALRN-6924 dose level will be assessed during Part 1. ALRN-6924 is given either 24 hr or 6 hr prior to each topotecan administration. Part 2 NSCLC of the study will be conducted in two stages. In Stage 1, a total of 20 patients will be randomized 1:1 to receive (with or without immunotherapy) either carboplatin plus pemetrexed plus ALRN-6924 or carboplatin plus pemetrexed plus placebo. During Stage 1 of Part 2 NSCLC, two interim analyses will be conducted after 10 and 20 patients, respectively, have been evaluated. The purpose of the two interim analyses is to confirm safety and exclude futility. In Stage 2 of Part 2 NSCLC, an additional 40 patients will be randomized to treatment as described for Stage 1. Immunotherapy and/or bevacizumab may be used concurrently with chemotherapy and after completion of 1st-line treatment (i.e., for maintenance purposes) as per local standard of care. Time of administration of immunotherapy and/or bevacizumab relative to chemotherapy will follow local standards of care.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Interventions

ALRN-6924DRUG

ALRN-6924 administered IV on Days 0-2 prior to carboplatin and pemetrexed administered IV on Day 1 of every 21-day cycle.

CarboplatinDRUG

Carboplatin administered IV on Day 1 of every 21-day cycle.

PemetrexedDRUG

Pemetrexed administered IV on Day 1 of every 21-day cycle.

PlaceboDRUG

Placebo administered IV on Days 0-2 prior to carboplatin and pemetrexed administered IV on Day 1 of every 21-day cycle.

ALRN-6924DRUG

ALRN-6924 administered IV on Days 0-4 prior to topotecan administered IV on Days 1-5 of every 21-day cycle.

TopotecanDRUG

Topotecan administered IV on Days 1-5 of every 21-day cycle.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Phase 1b, Part 2 NSCLC Inclusion Criteria: * Histopathological confirmation of Stage IV NSCLC of adenocarcinoma histology. Cytological diagnosis of NSCLC is acceptable if sufficient tumor tissue is available for p53 mutation analysis. FDA approved liquid biopsies are also acceptable. * Presence of one or more p53 mutations. * Measurable disease using RECIST 1.1. * Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1. * Adequate hematological status. * Adequate hepatic and renal function. Phase 1b, Part 2 NSCLC Exclusion Criteria: * Advanced NSCLC tumors with EGFR mutations or ALK re-arrangement or other actionable genetic aberrations for which an approved targeted treatment is available. Patients who received prior treatment with EGFR or ALK inhibitors or other systemic drugs or immunotherapy for NSCLC are not eligible. * Patients who are candidates for anti-PD-1 monotherapy in 1st line advanced NSCLC (e.g. tumors with high PD-L1 expression). * Presence of active central nervous system metastases and/or carcinomatous meningitis. * Significant weight loss (≥15% body weight) within the 4 weeks prior to enrollment. Phase 1b, Part 1 SCLC Inclusion Criteria: * Histopathological confirmation of ED SCLC that has recurred or been refractory to one line of treatment with standard platinum-based chemotherapy or immuno-chemotherapy. Patients who received immunotherapy after platinum-based chemotherapy are eligible. * Presence of one or more p53 mutations. * Measurable disease using RECIST 1.1. * Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2. * Adequate hematological status. * Adequate hepatic and renal function. Phase 1b, Part 1 SCLC Exclusion Criteria: * More than one line of prior chemotherapy for ED SCLC (prior immunotherapy is permitted, concurrent with or subsequent to first line chemotherapy). * Presence of active central nervous system metastases and/or carcinomatous meningitis. * Significant weight loss (≥15% body weight) within the 4 weeks prior to enrollment.

Locations (28)

Arizona Cancer Center

Kingman, Arizona, United States

Mount Sinai Cancer Research Program

Miami, Florida, United States

Oncology & Hematology Associates of West Broward

Tamarac, Florida, United States

H. Lee Moffitt Cancer Center & Research Institute

Tampa, Florida, United States

Regional Medical Oncolgy Center

Wilson, North Carolina, United States

Outcomes

Primary Outcomes

Phase 1b Part 2 NSCLC

Proportion of completed treatment cycles that are free of Grade ≥ 3 hematological toxicities (including neutropenia, anemia, thrombocytopenia and febrile neutropenia), and free of chemotherapy dose reductions, and free of use of growth factors and transfusions.

Time frame: Approximately 6 months

Phase 1b Part 1 SCLC

Proportion of patients with National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Grade 3/4 treatment emergent adverse events (TEAEs)

Time frame: Approximately 19 months